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Abstract Bordetella pertussis-specific antibodies can be
detected by enzyme-linked immunosorbent assays (ELISAs)
or multiplex immunoassays. Assays use purified or
mixed antigens, and only pertussis toxin (PT) is specific
for B. pertussis. The interpretation of results can be based
on dual-sample or single-sample serology using one or
two cut-offs. The EU Pertstrain group recommends that:
(i) ELISAs and multiplex immunoassays should use
purified non-detoxified PT as an antigen, that they should
have a broad linear range and that they should express
results quantitatively in International Units per millilitre
(IU/ml); (ii) a single or dual diagnostic cut-off for single-
serum serology using IgG-anti-PT between 50 and 120 IU/ml
should be used, and diagnostic serology cannot be validly
interpreted for one year after vaccination with acellular
pertussis (aP) vaccines; (iii) IgA-anti-PT should only be used
with indeterminate IgG-anti-PT levels or when a second
sample cannot be obtained. This group discourages using: (i)
other antigens in routine diagnostics, as they are not specific;
(ii) micro-agglutination, due to its lack of sensitivity; (iii)
immunoblots for pertussis serodiagnosis, as results cannot be
quantified;(iv)othermethods,suchascomplementfixationor
indirect immunofluorescence, due to their low sensitivity and/
or specificity.
Indications for pertussis diagnostics
The diagnosis ofpertussis shouldonlybe attemptedinpatients
with symptoms compatible with pertussis, such as prolonged
coughing with paroxysms and/or whooping or choking. In
infants, older vaccinated children, adolescents and adults, the
clinical course may not be typical, and prolonged coughing
may be the only symptom. In these cases, the diagnosis of
pertussis requires laboratory methods for confirmation.
Direct and indirect tests are available. Direct tests are
real-time polymerase chain reaction (PCR) and culture,
whereas indirect tests measure specific antibodies in oral
fluid or sera. Here, we focus on the detection of antibodies
against Bordetella pertussis antigens.
Development of the recommendations
The EU Pertstrain group consists of representatives of
the Bordetella reference laboratories in their respective
EU countries. In a face-to-face meeting at the Istituto
Superiore di Sanità (ISS), Rome, Italy, in 2009, the outline
of a manuscript was discussed and agreed upon. After a
search of relevant databases, a first draft was written (NG)
and intensively reviewed by members of the group. In a
second face-to-face meeting, at the Rijksinstituut voor
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Netherlands, in June 2010, the draft recommendations were
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was then reviewed again by all authors.
Serological tests
Blood/serum
Most serological assays are validated to test serum; some
may also be validated to test heparinised plasma or
ethylenediaminetetraacetic acid (EDTA) plasma. Capillary
blood samples may be used if a sufficient volume cannot be
obtained otherwise. Serum or plasma must be separated as
soon as possible after blood sampling (24 h at room
temperature). If acute and convalescent serum samples
taken at least three weeks apart from one individual are
available, they should be tested together in one run. All
serum samples may be frozen (at −20°C) after the primary
assay and re-analysed later together with a possible second
sample.
ELISA in serum samples
Inpreparationfortheacellularvaccinestudiesinthe1990s,the
enzyme-linked immunosorbent assay (ELISA) methodology,
the type of antigens, as well as the reference sera have been
standardised, and they have been used in all acellular vaccine
trials, in sero-epidemiological studies in many countries and
for diagnostic purposes in various laboratories [1–5].
Antigens
ELISA is normally done with highly purified antigens. The
antigens most frequently used are pertussis toxin (PT) and
filamentous haemagglutinin (FHA), and to a lesser extent,
pertactin (PRN) and fimbriae (FIM). Sometimes, adenylate
cyclase-haemolysin toxin (ACT) is also used. These
antigens are used in their active, i.e. non-detoxified, form.
The storage conditions of the antigens as well as the
duration of storage can vary significantly according to the
manufacturers who provide the purified antigens. Anti-PT
antibodies are specific for B. pertussis, whereas anti-FHA,
anti-PRN, anti-FIM and anti-ACT are less specific due to
cross-reactivity with other microbial antigens (e.g. other
Bordetella species, Haemophilus species, Mycoplasma
pneumoniae, Escherichia coli). For this reason, in routine
diagnosis, only the measurement of anti-PT antibodies is
recommended.However,the measurementofotherantibodies
may be used for transmission, immunogenicity or vaccine
non-inferiority studies. Some ELISAs, especially commercial
kits, use a mixture of antigens or supernatants or sonicates of
whole B. pertussis cells. The use of kits with mixed antigens
is not recommended [6].
Reference sera
World Health Organization (WHO) references are available
from the National Institute for Biological Standards and
Control (NIBSC, Potters Bar, UK) (“WHO International
Standard (06/140)” and “WHO Reference Reagent (06/
142)”) for the measurement of human antibodies to B.
pertussis antigens, and, thus, quantitative results should be
reported in IU/ml [7].
Plates
For in-house ELISAs, differences between plates were
observed, and Thermo Scientific Nunc MaxiSorp (Nunc AS,
Copenhagen, Denmark) plates and Greiner MICROLON
High Binding (Greiner Bio-One, Frickenhausen, Germany)
plates seemed to work better than others [8].
Flow cytometry
Bead-based multiplex assays that simultaneously measure
antibodies to various antigens have also been applied to B.
pertussis antigens. The assays use fluorescent micropar-
ticles to which purified antigens are covalently coupled and
are based on a proprietary method patented in 1983 in
Germany [9] or on xMAP Technology from Luminex™
[10]. These assays seem to produce results comparable to
conventional ELISA systems.
Immunoblots, line and dot blots
Many commercial kits detect anti-B. pertussis and/or anti-PT,
anti-FHA, anti-PRN and also ACTantibodies in serums using
blotting techniques. Kits using whole-cell suspensions as
antigens are not specific for the detection/diagnosis of
pertussis infections due to the great cross-reactivity with
other bacteria (e.g. other Bordetella species, Haemophilus
species, Mycoplasma pneumoniae). Antigens used in these
kits have to be validated concerning their purity, as
contamination with other antigens or antigen aggregates can
also produce false-positive results. A quantitative interpreta-
tion of blot results is not possible, but a semi-quantitative
reporting may be possible. Although various CE-marked
commercial kits are available, a recent comparison showed
significant differences between kits and an insufficient
correlation to the values of the 1st International Reference
Preparation (Kennerkuecht et al. submitted). Consequently,
the use of immunoblots for pertussis serology is not
recommended by the EU Pertstrain group.
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Micro-agglutination has been widely used before ELISA
systems became available [11]. As with other bacterial
agglutination assays, micro-agglutination with B. pertussis
cells mainly measures IgM antibodies to outer surface
antigens such as FIM, PRN and lipooligosaccharide (LOS).
Results are reported in titres starting at 1:20 or 1:40. No
agglutinin titre has been attributed to the WHO reference
preparation so far. Agglutinating antibodies can be used to
measure the exposure of a population to B. pertussis antigens;
on an individual level, the micro-agglutination method is not
useful for confirming the clinical diagnosis of pertussis.
CHO cell neutralisation
This test used the ability of PT to induce characteristic
morphological changes in a culture of Chinese hamster ovary
(CHO) cells.Thesechangescanbe neutralisedbythepresence
of anti-PT antibodies. The titres of CHO cell-neutralising
antibodies correlate well with the IgG-anti-PT ELISA values,
and, thus, CHO cell assays are rarely used for diagnostic
purposes[8, 12]. The interpretation of CHO assays cannot be
standardised, and it is difficult to interpret the morphological
changes and to score the results objectively.
Complement fixation
Complement fixation using whole cells of B. pertussis has
been rarely used and suffers from a lack of sensitivity and
specificity.
Indirect immunofluorescence
IndirectimmunofluorescenceusingwholecellsofB. pertussis
has the same disadvantages as complement fixation
Oral fluid
Oral fluid can be sampled by standardised means, e.g.
Oracol swabs (Malvern Medical Developments) or OraSure
oral specimen collection devices (OraSure Technologies
Inc.). The diagnostic sensitivity of measuring antibodies in
oral fluid samples is lower (∼80%) as compared to serum
samples, but the samples can easily be obtained and offer
an adjunct to diagnostic serology
ELISA in oral fluid
An IgG-capture ELISA capable of detecting anti-PT IgG in
oral fluid has been developed. The assay was evaluated by
comparison to a serum ELISA. The results showed that the
oralfluidassaydetectedseropositivesubjectswithasensitivity
of 79.7% [95% confidence interval (CI) 68.3–88.4] and a
specificity of 96.6% (95% CI 91.5–99.1)relative totheELISA
[13]. This assay has since been modified to include a
monoclonal capture antibody; however, no commercial
assays for measuring antibodies in oral fluid are available.
Reporting of serological results using ELISA or flow
cytometry
Concentrations of antibodies to B. pertussis antigens should
be quantitatively expressed in IU/ml as reference preparations
are available [7]. The reference preparation defines values for
antibodies of isotypes IgG and IgA to PT, FHA, PRN and to
FIM. Assigned values of the reference preparation are
described in Table 1. The numerical values of IU/ml are
equivalent to the previously used ELISA units/ml (EU/ml)
derived from the human reference preparations lot 3, lot 4
and lot 5 from the Center for Biologics Evaluation and
Research/Food and Drug Administration (CBER/FDA),
Bethesda, MD, USA.
Interpretation of serological results
PTand FHA are contained in substantial amountsin all acellular
vaccines licensed in Europe (except in Denmark), and PRN and
FIM are also components of licensed acellular pertussis
vaccines. Thus, the immune response against infection or
vaccination cannot be distinguished and pertussis vaccination
may interfere with the interpretation of serological results. Due
to a continuous circulation of Bordetellae in the population,
IgG-anti-PT and other antibodies to Bordetella antigens are
detectable in the majority of all adolescent and adult
populations tested so far [14]. Thus, serological diagnosis of
pertussis must be performed in immunological non-naïve
populations with different kinetics of antibody production.
Additionally, pertussis serology suffers from various other
drawbacks:
– Commercial ELISAs are of different antigen composition
and quality
– Reference antigens with good purityarenot easily available
– Population-based cut-offs for single-sample serology may
needverificationafterchangesinthevaccinationschedule
– Interpretation of anti-PT concentrations in recently
vaccinated persons is difficult
Dual-sample serology based on ≥100% increase in
antibody concentration or on ≥50% decrease in antibody
concentration is a sensitive and specific method for
serological diagnosis [1, 4]. However, even in paired sera,
no antibody increase may be seen after infection due to the
secondary immune response, and the diagnosis may also be
Eur J Clin Microbiol Infect Dis (2011) 30:307–312 309based on a decrease of antibodies, which may be too slow
to reach 50% between the acute and convalescent sample.
In clinical practice, diagnosis is mostly based on single-
sample serology using a single or a more continuous cut-
off. For single-sample serology, various cut-off values for
IgG-anti-PT have been proposed (Table 2). In Massachu-
setts, 100 EU/ml was used, and, later, in order to increase
specificity, >∼200 EU/ml IgG-anti-PT (>20 μg/ml) was
employed. In the Netherlands, a cut-off >∼125 EU/ml IgG-
anti-PT with higher specificity or 62 EU/ml with slightly
lower specificity has been used [15, 16]. In Germany, a cut-
off of ∼40 EU/ml IgG-anti-PT was suggested, together with
∼50 EU/ml IgA-anti-FHA. A sero-epidemiological survey
was recently performed in various countries in Western
Europe using a cut-off of 125 EU/ml for recent infection,
and it can be used as a population-based reference [14].
Another recently completed sero-surveillance in US sera
found that three populations could be separated according
to their levels of IgG-anti-PT: one cut-off was estimated at
94 EU/ml and a lower cut-off was estimated at 48 EU/ml
[17]. Using the lower 50 EU/ml cut-off may be especially
useful in outbreak situations, and, overall, this cut-off of 50
EU/ml seems to be more appropriate for diagnosis rather
than a higher cut-off with lower sensitivity [18].
Overall, it is astonishing that, irrespective of various
vaccination strategies, cut-offs for single-sample serology
are comparable throughout the countries in which they were
evaluated.
A comparison of receiver operating characteristic (ROC)
curve analyses with data from Denmark, the Netherlands
and the UK showed that, for all three countries, the single
cut-off with optimal sensitivity and specificity may be in
the range between 60 and 75 IU/ml.
It may be sensible to use a dual cut-off between 62 and
125 IU/ml according to countries as a proof of a recent
infection with B. pertussis, provided that the patient was not
vaccinated during the last 12 months (Table 2). If diagnosis
cannot be established with certainty from a single serum, but
is deemed to be necessary according to the clinical symptoms,
antibodies should be measured in a second (convalescent)
serum sample at two to four weeks interval. In case of non-
availability of a second serum sample, measurement of IgA
anti-PT antibodies can be an alternative, but no broadly
accepted cut-off is available for this antibody subclass.
Considering its relatively high specificity and low sensitivity,
a cut-off near the minimal level of quantification, which may
be between 10 and 20 IU/ml, may seem reasonable [19].
Recommendations for serological testing with suspected
pertussis
In neonates and young infants, PCR and/or culture should
be performed on nasopharyngeal samples, nasopharyngeal
swabs (NPSs) or nasopharyngeal aspirates (NPAs) as soon
as possible post-onset of symptoms. The measurement of
Table 1 Reference preparations from the World Health Organization
(WHO) and the Center for Biologics Evaluation and Research/Food
and Drug Administration (CBER/FDA). Values are given in IU/ml for
the WHO preparations and in ELISA units (EU)/ml for the CBER/
FDA preparations; IU/ml and EU/ml are numerically identical [7]
IgG-anti-PT IgA-anti-PT IgG-anti-FHA IgA-anti-FHA IgG-anti-PRN IgA-anti-PRN
WHO international standard (06/140) 335 IU/ml 65 IU/ml 130 IU/ml 65 IU/ml 65 IU/ml 42 IU/ml
WHO reference reagent (06/142) 106 IU/ml 18 IU/ml 122 IU/ml 86 IU/ml 39 IU/ml 38 IU/ml
CBER/FDA #3 200 EU/ml 15 EU/ml 200 EU/ml 100 EU/ml ND ND
CBER/FDA #5 ND 140 EU/ml ND 280 EU/ml ND 90 EU/ml
CBER/FDA #4 ND ND ND ND 90 EU/ml 25 EU/ml
ND, not declared
Country Type of study Cut-off Sensitivity Specificity Reference
MA, USA Population study ∼100 IU/ml 78% 98% [20]
MA, USA Population study ∼200 IU/ml 67% 99.9% [21]
NL Population study 125 IU/ml 70% 99% [15]
62 IU/ml 80% 95%
D Population study 40 IU/ml 80% 95% [22]
EU Epidemiological survey 125 IU/ml n.a. n.a. [14]
USA Epidemiological survey, model 94 IU/ml n.a. n.a. [17]
46 IU/ml n.a.
AUS Clinical validation 50 IU/ml Better than 100 IU/ml [18]
Table 2 Suggested cut-off
values for IgG-anti-PT for ado-
lescents and adults. Adapted from
WHO “The Immunological Basis
for Immunization Series”
(available online at: http://
whqlibdoc.who.int/publications/
2010/9789241599337_eng.pdf)
MA, Massachusetts
n.a., not applicable
310 Eur J Clin Microbiol Infect Dis (2011) 30:307–312IgG-anti-PT is only meaningful for older children/adults,
including parents and other household members. In
vaccinated children, adolescents and adults with less than
two weeks of coughing culture and PCR from nasopharyn-
geal samples should be done. For adolescents and adults
with coughing of less than three weeks, PCR and the
measurement of IgG-anti-PT should be performed [1]. If
coughing lasted at least 2 to 3 weeks, the measurement of
IgG-anti-PT should be sufficient. In outbreak situations,
PCR and culture should be performed from nasopharyngeal
samples and IgG-anti-PT should be measured in serum
samples.
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